Literature DB >> 17971431

Mortality in acromegaly: a metaanalysis.

O M Dekkers1, N R Biermasz, A M Pereira, J A Romijn, J P Vandenbroucke.   

Abstract

CONTEXT: Several studies have assessed mortality risk in patients treated for acromegaly. All studies found a mortality that was higher than expected for the general population, but most of these increases were not statistically significant. For this reason, it is not formally established whether mortality in acromegaly is different from the general population.
OBJECTIVE: The objective of the study was to address the all-cause mortality risk in patients with acromegaly.
DESIGN: The study was a metaanalysis.
METHODS: Sixteen studies on mortality in patients with acromegaly were included. The principal outcome of the metaanalysis was the weighted average of the standardized mortality ratio (SMR) of all studies. In addition, we performed a subgroup analysis of studies in which more than 80% of the patients were treated by transsphenoidal approach.
RESULTS: The weighted mean of the SMR from all 16 studies was 1.72 (95% confidence interval 1.62-1.83). In studies with transsphenoidal surgery as the primary therapy, the weighted mean of the SMR was 1.32 (95% confidence interval 1.12-1.56).
CONCLUSIONS: This metaanalysis shows increased all-cause mortality in acromegalic patients, compared with the general population, even after transsphenoidal surgery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17971431     DOI: 10.1210/jc.2007-1191

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  122 in total

1.  Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients.

Authors:  Mai Christiansen Arlien-Søborg; Christian Trolle; Elin Alvarson; Amanda Bæk; Jakob Dal; Jens Otto Lunde Jørgensen
Journal:  Endocrine       Date:  2017-03-04       Impact factor: 3.633

2.  Pituitary gland: New consensus in acromegaly: criteria for cure and control.

Authors:  Nienke Biermasz
Journal:  Nat Rev Endocrinol       Date:  2010-09       Impact factor: 43.330

Review 3.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

4.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

5.  Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly.

Authors:  E Lin; T L Wexler; L Nachtigall; N Tritos; B Swearingen; L Hemphill; J Loeffler; B M K Biller; A Klibanski; K K Miller
Journal:  Clin Endocrinol (Oxf)       Date:  2012-09       Impact factor: 3.478

Review 6.  Update on prognostic factors in acromegaly: Is a risk score possible?

Authors:  E Fernandez-Rodriguez; F F Casanueva; I Bernabeu
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

Review 7.  Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.

Authors:  Ana M Ramos-Leví; Mónica Marazuela
Journal:  Endocrine       Date:  2017-01-02       Impact factor: 3.633

8.  Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study.

Authors:  Chris G Yedinak; Maria Fleseriu
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

9.  Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas.

Authors:  Yifan Tang; Tao Xie; Silin Wu; Qiaoqiao Yang; Tengfei Liu; Chen Li; Shuang Liu; Zhiyong Shao; Xiaobiao Zhang
Journal:  Endocrine       Date:  2021-05-27       Impact factor: 3.633

Review 10.  The role of combination medical therapy in the treatment of acromegaly.

Authors:  Dawn Shao Ting Lim; Maria Fleseriu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.